Clinical Trial Update: PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating QL1706 plus chemotherapy and bevacizumab in PD-L1 ≥50% non-squamous non-small cell lung cancer; the trial is currently not yet recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• QL1706

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Lung Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING